Eton Pharmaceuticals, Inc. Class of Warrant or Right, Outstanding
Eton Pharmaceuticals, Inc. (ETON) had Class of Warrant or Right, Outstanding of 359.12 thousand shares as of 2024-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2025-03-18
- 2024-12-31: Class of Warrant or Right, Outstanding 359.12K shares.
- 2024-09-30: Class of Warrant or Right, Outstanding 359.12K shares.
- 2024-06-30: Class of Warrant or Right, Outstanding 69.38K shares.
- 2024-03-31: Class of Warrant or Right, Outstanding 69.38K shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2024-12-31 | 359.12K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 359.12K shares 10-Q · filed 2024-11-12 |
| 2024-06-30 | 69.38K shares 10-Q · filed 2024-08-08 |
| 2024-03-31 | 69.38K shares 10-Q · filed 2024-05-09 |
| 2023-12-31 | 69.38K shares 10-K · filed 2025-03-18 |
| 2023-09-30 | 483.38K shares 10-Q · filed 2023-11-09 |
| 2023-06-30 | 483.38K shares 10-Q · filed 2023-08-10 |
| 2023-03-31 | 483.38K shares 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |